Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/47549 |
Resumo: | Mitochondrial toxicity has resulted in the withdrawal of several drugs from the market. One particular example is nefazodone, an anti-depressant withdrawn in the USA due to hepatoxicity caused by drug-induced mitochondrial dysfunction. Drug development and safety testing can involve the use of large numbers of laboratory animals, which, without a decisive pre-screening for mitochondrial toxicity, are often unable to pre-empt higher mortality rates in some patient groups. The use of isolated mitochondria as a screening tool for drug safety can decrease the number of laboratory animals used in pre-clinical studies, thus improving animal welfare and healthcare outcomes and costs. Novel techniques involving high-throughput methods can be used to investigate whether a molecule is a mitochondrial toxicant. Moreover, these screens are mechanistically-based, since the effects of the drug on oxidative phosphorylation, calcium homeostasis and mitochondrial genetics can be assessed. This review is intended to demonstrate that isolated mitochondrial fractions are suitable for predicting drug and general chemical safety in toxicological screenings, thus contributing to the refinement and reduction of animal use in laboratory research. |
id |
RCAP_caa606b5c34f23876be2b4c0cc6cdaa7 |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/47549 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions?AnimalsCell FractionationDrug Evaluation, PreclinicalDrug-Related Side Effects and Adverse ReactionsHigh-Throughput Screening AssaysHumansMembrane Potential, MitochondrialMitochondriaMitochondrial Membrane Transport ProteinsModels, AnimalPermeabilityPredictive Value of TestsRisk AssessmentXenobioticsAnimal Testing AlternativesAnimals, LaboratoryMitochondrial toxicity has resulted in the withdrawal of several drugs from the market. One particular example is nefazodone, an anti-depressant withdrawn in the USA due to hepatoxicity caused by drug-induced mitochondrial dysfunction. Drug development and safety testing can involve the use of large numbers of laboratory animals, which, without a decisive pre-screening for mitochondrial toxicity, are often unable to pre-empt higher mortality rates in some patient groups. The use of isolated mitochondria as a screening tool for drug safety can decrease the number of laboratory animals used in pre-clinical studies, thus improving animal welfare and healthcare outcomes and costs. Novel techniques involving high-throughput methods can be used to investigate whether a molecule is a mitochondrial toxicant. Moreover, these screens are mechanistically-based, since the effects of the drug on oxidative phosphorylation, calcium homeostasis and mitochondrial genetics can be assessed. This review is intended to demonstrate that isolated mitochondrial fractions are suitable for predicting drug and general chemical safety in toxicological screenings, thus contributing to the refinement and reduction of animal use in laboratory research.2009-09info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/47549http://hdl.handle.net/10316/47549porPereira, Susana P.Pereira, Gonçalo C.Moreno, António J.Oliveira, Paulo J.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2021-10-11T11:09:23Zoai:estudogeral.uc.pt:10316/47549Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:53:38.364813Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? |
title |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? |
spellingShingle |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? Pereira, Susana P. Animals Cell Fractionation Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions High-Throughput Screening Assays Humans Membrane Potential, Mitochondrial Mitochondria Mitochondrial Membrane Transport Proteins Models, Animal Permeability Predictive Value of Tests Risk Assessment Xenobiotics Animal Testing Alternatives Animals, Laboratory |
title_short |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? |
title_full |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? |
title_fullStr |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? |
title_full_unstemmed |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? |
title_sort |
Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? |
author |
Pereira, Susana P. |
author_facet |
Pereira, Susana P. Pereira, Gonçalo C. Moreno, António J. Oliveira, Paulo J. |
author_role |
author |
author2 |
Pereira, Gonçalo C. Moreno, António J. Oliveira, Paulo J. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Pereira, Susana P. Pereira, Gonçalo C. Moreno, António J. Oliveira, Paulo J. |
dc.subject.por.fl_str_mv |
Animals Cell Fractionation Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions High-Throughput Screening Assays Humans Membrane Potential, Mitochondrial Mitochondria Mitochondrial Membrane Transport Proteins Models, Animal Permeability Predictive Value of Tests Risk Assessment Xenobiotics Animal Testing Alternatives Animals, Laboratory |
topic |
Animals Cell Fractionation Drug Evaluation, Preclinical Drug-Related Side Effects and Adverse Reactions High-Throughput Screening Assays Humans Membrane Potential, Mitochondrial Mitochondria Mitochondrial Membrane Transport Proteins Models, Animal Permeability Predictive Value of Tests Risk Assessment Xenobiotics Animal Testing Alternatives Animals, Laboratory |
description |
Mitochondrial toxicity has resulted in the withdrawal of several drugs from the market. One particular example is nefazodone, an anti-depressant withdrawn in the USA due to hepatoxicity caused by drug-induced mitochondrial dysfunction. Drug development and safety testing can involve the use of large numbers of laboratory animals, which, without a decisive pre-screening for mitochondrial toxicity, are often unable to pre-empt higher mortality rates in some patient groups. The use of isolated mitochondria as a screening tool for drug safety can decrease the number of laboratory animals used in pre-clinical studies, thus improving animal welfare and healthcare outcomes and costs. Novel techniques involving high-throughput methods can be used to investigate whether a molecule is a mitochondrial toxicant. Moreover, these screens are mechanistically-based, since the effects of the drug on oxidative phosphorylation, calcium homeostasis and mitochondrial genetics can be assessed. This review is intended to demonstrate that isolated mitochondrial fractions are suitable for predicting drug and general chemical safety in toxicological screenings, thus contributing to the refinement and reduction of animal use in laboratory research. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-09 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/47549 http://hdl.handle.net/10316/47549 |
url |
http://hdl.handle.net/10316/47549 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133822924619776 |